Nanolattix's Nuclear Drug RT01 Completes First Dosing in Clinical IIT, Seizing the New High Ground of "RDC + ADC" Theranostics Integration
Release time:
2026-03-03
Currently, China's nuclear drug industry is experiencing explosive growth, with a compound annual growth rate exceeding 20%. Amidst this industry wave driven by "source innovation," Nanolattix, with its forward-looking layout of "RDC + ADC" dual-track innovation, has become one of the earliest systematic innovators in the domestic nuclear drug field.
The first theranostic radionuclide-drug conjugate (RDC) independently developed by Nanolattix, RT01, has reached a key milestone — successfully entering an investigator-initiated trial (IIT) and completing the first dosing of enrolled subjects. Through continuous PET/CT imaging at six time points, RT01 has demonstrated time-dependent radioactive tumor enrichment characteristics and excellent target-to-background contrast. Preliminary results confirm that the drug has a long retention time in tumor tissue, providing strong support for its subsequent therapeutic effect. Currently, this clinical research is progressing steadily.
The clinical progress of RT01 offers a window into Nanolattix’s deep insight into the evolving landscape of the nuclear medicine industry. At its core, modern radiopharmaceuticals represent a deep integration of nuclear physics, life sciences, and biotechnology. In China, robust capabilities have already been established in biopharmaceutical fields such as antibody engineering and CMC, while the medical nuclide supply chain is rapidly maturing—providing essential upstream support for independent innovation in nuclear medicine. At the same time, China’s large cancer patient population creates urgent demand for more effective therapies, continuously forcing the need for real-world clinical solutions. Meanwhile, the regulatory and investment environment is increasingly favoring innovative therapies with proven clinical value. Driven by this conviction, Nanolattix made an early strategic move into the nuclear medicine space in 2018, witnessing and contributing to the country’s shift in innovative drug development—from “follow-on innovation” to “source innovation” and “systematic innovation.”As targeted radiopharmaceuticals approach an industrial-scale breakthrough, the synergistic pathway of “RDC + ADC theranostics”may well redefine the paradigm of nuclear medicine innovation.
Tag:
recommend News
Share
